Hoppa till innehål
banner-mesenkia-8

International Research Collaboration Brings Hope for Glioblastoma Treatment

From Research to Innovation: The Story Behind Mesenkia Therapeutics

Mesenkia Therapeutics is building on years of collaborative research conducted by scientists at Uppsala University and the University of Tokyo with the goal of developing a new treatment for glioblastoma.

The article highlights the scientific discoveries behind the company’s work, the international collaboration that made the research possible, and the steps required to translate promising laboratory findings into a potential future therapy.

Read the full article below to learn more about the research, the collaboration, and Mesenkia’s mission to advance new treatment options for patients with glioblastoma.

Read full article here

More news

See all news

New Preclinical Findings Identify HVEM as a Promising Target in Aggressive Glioblastoma

Researchers have identified HVEM as a promising therapeutic target in mesenchymal glioblastoma...

Kohei Miyazono new member at the royal Swedish academy of science.

Kohei Miyazono has been elected as a new member to the Academy’s class for medical sciences at the royal ...

US Patent Application IP001 Receives Notice of Allowance

The US patent application IP001 has received an allowance for protection of our novel HVEM antagonistic single domain antibodies.

Cookiesamtycke

På webbplatsen används nödvändiga kakor för att webbplatsen ska fungera på ett bra sätt. Du kan även välja att samtycka till kakor för statistikinsamling.